A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Reparixin (Primary)
- Indications COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms REPAVID-19 fase 3
- Sponsors Dompe Farmaceutici
- 05 Oct 2023 Results determining whether reparixin could reduce disease progression in patients hospitalized with severe COVID-19 pneumonia, published in the Infectious Diseases and Therapy
- 14 Jan 2022 Status changed from recruiting to completed.
- 03 Sep 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2021.